Sagimet Biosciences Inc.
For the period ended Jun 30, 2025. Filed Aug 13, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 13, 2025
SGMT$10.83+9.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets (unaudited)
CONDENSED BALANCE SHEETS
(in thousands, except for share and per share amounts)
| | | | | | | |
|---|---|---|---|---|---|---|
| · · As of | ||||||
| · · June 30, · · December 31, | ||||||
| | 2025 | 2024 | ||||
| Assets | | | | | | |
| Current assets: · · | ||||||
| Cash and cash equivalents | | $42,327 | | $75,840 | ||
| Short-term marketable securities | | 83,080 | | 75,410 | ||
| Prepaid expenses and other current assets | | | 1,789 | | | 1,524 |
| Total current assets | | | 127,196 | | | 152,774 |
| Long-term marketable securities | | | 10,059 | | | 7,408 |
| Operating lease right-of-use assets | | | 152 | | | 77 |
| Total assets | | $137,407 | | $160,259 | ||
| Liabilities and stockholders’ equity | | | ||||
| Current liabilities: | | | ||||
| Accounts payable | | $1,921 | | $1,425 | ||
| Accrued expenses and other current liabilities | | 5,174 | | 2,951 | ||
| Operating lease liabilities | | 152 | | 78 | ||
| Total current liabilities | | 7,247 | | 4,454 | ||
| Commitments and contingencies (Note 6) | | | ||||
| Stockholders’ equity: | | | ||||
| Undesignated preferred stock, $0.0001 per share: 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2025 and December 31, 2024 | | | — | | | — |
| Series A common stock, $0.0001 per share: 500,000,000 shares authorized; 30,674,954 shares issued and outstanding at June 30, 2025; 30,674,855 shares issued and outstanding at December 31, 2024 | | | 3 | | | 3 |
| Series B common stock, $0.0001 per share: 15,000,000 shares authorized; 1,520,490 shares issued and outstanding at June 30, 2025 and December 31, 2024 | | | — | | | — |
| Additional paid-in capital | | 453,954 | | 450,883 | ||
| Accumulated deficit | | (323,873) | | (295,311) | ||
| Accumulated other comprehensive income | | 76 | | 230 | ||
| Total stockholders’ equity | | | 130,160 | | 155,805 | |
| Total liabilities and stockholders’ equity | | $137,407 | | $160,259 | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.